Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.34 USD
-0.29 (-7.99%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $3.32 -0.02 (-0.60%) 4:46 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABUS 3.34 -0.29(-7.99%)
Will ABUS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Other News for ABUS
Arbutus Reports Promising Hepatitis B Trial Results
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300
Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300